Johnson & Johnson (NYSE:JNJ) EVP Vanessa Broadhurst Sells 23,054 Shares

Johnson & Johnson (NYSE:JNJ) EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. This trade represents a 50.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Johnson & Johnson Stock Performance

JNJ stock traded up $3.29 during midday trading on Tuesday, hitting $269.24. 3,058,960 shares of the stock traded hands, compared to its average volume of 8,408,270. Johnson & Johnson has a 1-year low of $164.23 and a 1-year high of $274.90. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.09 and a quick ratio of 0.81. The stock’s fifty day simple moving average is $243.46 and its 200-day simple moving average is $236.98. The firm has a market cap of $648.85 billion, a P/E ratio of 31.30, a PEG ratio of 2.50 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, topping analysts’ consensus estimates of $2.84 by $0.06. Johnson & Johnson had a net margin of 21.48% and a return on equity of 32.42%. The business had revenue of $25.31 billion during the quarter, compared to the consensus estimate of $25.06 billion. During the same quarter in the prior year, the firm posted $2.77 earnings per share. The company’s revenue was up 6.6% compared to the same quarter last year. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, analysts expect that Johnson & Johnson will post 11.68 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Investors of record on Tuesday, August 25th will be issued a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, August 25th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio is presently 62.11%.

Institutional Trading of Johnson & Johnson

Hedge funds have recently bought and sold shares of the business. Silver Coast Investments LLC grew its position in shares of Johnson & Johnson by 3.8% in the second quarter. Silver Coast Investments LLC now owns 1,066 shares of the company’s stock valued at $271,000 after purchasing an additional 39 shares in the last quarter. Townsend Asset Management Corp NC ADV lifted its position in Johnson & Johnson by 0.6% during the second quarter. Townsend Asset Management Corp NC ADV now owns 6,418 shares of the company’s stock worth $1,630,000 after buying an additional 39 shares in the last quarter. Sierra Capital LLC boosted its stake in Johnson & Johnson by 0.5% during the fourth quarter. Sierra Capital LLC now owns 8,144 shares of the company’s stock worth $1,685,000 after buying an additional 41 shares during the last quarter. Beaird Harris Wealth Management LLC boosted its stake in Johnson & Johnson by 1.8% during the fourth quarter. Beaird Harris Wealth Management LLC now owns 2,422 shares of the company’s stock worth $501,000 after buying an additional 42 shares during the last quarter. Finally, Ballast Advisors LLC grew its holdings in Johnson & Johnson by 1.2% in the 1st quarter. Ballast Advisors LLC now owns 3,598 shares of the company’s stock valued at $879,000 after buying an additional 42 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Scotiabank restated an “outperform” rating and issued a $305.00 price objective on shares of Johnson & Johnson in a research report on Thursday, July 16th. Sanford C. Bernstein lifted their price target on shares of Johnson & Johnson from $225.00 to $251.00 and gave the company a “market perform” rating in a research note on Wednesday, April 15th. The Goldman Sachs Group reissued a “buy” rating and issued a $282.00 price target on shares of Johnson & Johnson in a report on Thursday, July 16th. Weiss Ratings upgraded shares of Johnson & Johnson from a “buy (b-)” rating to a “buy (b)” rating in a research report on Friday. Finally, Johnson Rice upgraded shares of Johnson & Johnson from an “outperform” rating to a “buy” rating and set a $280.00 target price on the stock in a research report on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $265.30.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson agreed to pay $5.5 billion to resolve approximately 76,000 remaining U.S. lawsuits alleging that its talc products caused ovarian cancer. The proposed resolution could remove a major legal overhang and improve visibility into the company’s future liabilities. The agreement requires participation from at least 95% of remaining claimants, so completion is not yet guaranteed. Johnson & Johnson announces $5.5 billion settlement of talc lawsuits
• Positive Sentiment: Analysts at Goldman Sachs and Morgan Stanley reiterated Buy ratings following the settlement announcement, saying progress on talc claims reduces a significant uncertainty. Their price targets remained above the recent trading level at $282 and $294, respectively. Goldman Sachs reiterates Buy rating
• Positive Sentiment: Recent second-quarter results also support investor sentiment: revenue increased 6.6% year over year to $25.31 billion, adjusted earnings per share reached $2.90 and exceeded expectations, and Johnson & Johnson raised its full-year 2026 earnings outlook to $11.60–$11.75 per share. Johnson & Johnson raised its outlook
• Neutral Sentiment: The settlement carries a meaningful $5.5 billion financial cost and remains conditional on claimant participation, leaving execution and final approval risks for investors to monitor. Johnson & Johnson proposes talc settlement
• Negative Sentiment: Johnson & Johnson’s MedTech growth slowed in the second quarter, particularly in Cardiovascular, although stronger Vision, Surgery and Orthopedics results and new product launches could support improvement in the second half. J&J’s MedTech performance slows in Q2

About Johnson & Johnson

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.